Found: 18
Select item for more details and to access through your institution.
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2687, doi. 10.1111/dom.14522
- By:
- Publication type:
- Article
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2694, doi. 10.1111/dom.13859
- By:
- Publication type:
- Article
Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2674, doi. 10.1111/dom.13856
- By:
- Publication type:
- Article
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2694, doi. 10.1111/dom.13859
- By:
- Publication type:
- Article
Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2674, doi. 10.1111/dom.13856
- By:
- Publication type:
- Article
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1202, doi. 10.1111/dom.13218
- By:
- Publication type:
- Article
Cover Image, Volume 20, Issue 2.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. i, doi. 10.1111/dom.13195
- By:
- Publication type:
- Article
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 378, doi. 10.1111/dom.13082
- By:
- Publication type:
- Article
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
- Published in:
- 2018
- By:
- Publication type:
- journal article
85-LB: RESULTADOS DE LA MCG Y DE LA DURACION DE HIPOGLUCEMIA CON INSULINA ICODEC UNA VEZ A LA SEMANA VS. INSULINA GLARGINA U100 UNA VEZ AL DÍA EN PACIENTES CON T2D NO TRATADA CON INSULINA-ONWARDS 1 UN ANÁLISIS EXPLORATORIO.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 19
- By:
- Publication type:
- Article
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 12, p. 1971, doi. 10.1111/jdi.13905
- By:
- Publication type:
- Article
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 7, p. 1161, doi. 10.1111/jdi.13773
- By:
- Publication type:
- Article
Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 9, p. 1610, doi. 10.1111/jdi.13525
- By:
- Publication type:
- Article
Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart.
- Published in:
- Journal of Diabetes Investigation, 2018, v. 9, n. 2, p. 303, doi. 10.1111/jdi.12697
- By:
- Publication type:
- Article
Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.
- Published in:
- Journal of Diabetes Investigation, 2013, v. 4, n. 1, p. 62, doi. 10.1111/j.2040-1124.2012.00240.x
- By:
- Publication type:
- Article
Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.
- Published in:
- Journal of Diabetes Investigation, 2011, v. 2, n. 6, p. 441, doi. 10.1111/j.2040-1124.2011.00128.x
- By:
- Publication type:
- Article
Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.
- Published in:
- Journal of Diabetes Investigation, 2011, v. 2, n. 4, p. 280, doi. 10.1111/j.2040-1124.2011.00103.x
- By:
- Publication type:
- Article
28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
- Published in:
- Journal of Diabetes Investigation, 2010, v. 1, n. 3, p. 103, doi. 10.1111/j.2040-1124.2010.00015.x
- By:
- Publication type:
- Article